Institute of Medical Microbiology, University Hospital Münster, Münster, Germany.
Friedrich Loeffler-Institute of Medical Microbiology, University Medicine Greifswald, Greifswald, Germany.
Microb Drug Resist. 2020 Nov;26(11):1405-1409. doi: 10.1089/mdr.2019.0390. Epub 2020 Mar 17.
Revival of old antibiotic compounds is a promising strategy to strengthen the antimicrobial armamentarium in the era of increasing resistance and limited development pipelines. To exploit their full potential, their reinvestigation using current standards is needed. We aimed to investigate the activity of the old antimicrobial agent sodium bituminosulfonate in accordance with the current recommendations for antimicrobial susceptibility testing (AST) and to generate susceptibility data reflecting the current epidemiological situation. The activity of sodium bituminosulfonate was tested on consecutive clinical isolates, including 12 methicillin-resistant (MRSA) and 12 methicillin-susceptible (MSSA), 24 coagulase-negative staphylococci (CoNS), 60 streptococci, 12 , 12 (including two vancomycin-resistant strains), 12 , 12 nonfermenting Gram-negative bacilli, and 12 [] . AST of sodium bituminosulfonate was performed using broth microdilution method for Gram-positive cocci and Gram-negative rods and by agar dilution method for . Sodium bituminosulfonate demonstrated activity against Gram-positive pathogens with minimal inhibitory concentration 90 (MIC) values (g/L) for MRSA 0.25, MSSA 1, CoNS 16, 0.03, 0.125, ≤0.015, ≤0.015, viridans streptococci 0.03, 0.25, 0.5, and 0.03 (without blood supplement). MIC values for Gram-negative bacteria were considerably higher. Blood-supplemented media proved to be unsuitable for activity testing of this agent. Sodium bituminosulfonate may represent an alternative to classical antibiotics for topical use. Although it has been clinically used for many decades, well-designed randomized trials are needed for the effective revival of this old antimicrobial.
老抗生素化合物的复兴是在耐药性不断增加和开发管道有限的时代加强抗菌武器库的有前途的策略。为了充分发挥其潜力,需要使用当前的标准对其进行重新研究。我们旨在根据当前抗菌药物敏感性测试(AST)建议调查旧抗菌剂磺酸钠的活性,并生成反映当前流行病学情况的药敏数据。对连续的临床分离株进行了磺酸钠的活性测试,包括 12 株耐甲氧西林金黄色葡萄球菌(MRSA)和 12 株甲氧西林敏感金黄色葡萄球菌(MSSA)、24 株凝固酶阴性葡萄球菌(CoNS)、60 株链球菌、12 株肠球菌、12 株屎肠球菌(包括 2 株耐万古霉素菌株)、12 株非发酵革兰氏阴性杆菌和 12 株淋病奈瑟菌 [] 。使用肉汤微量稀释法和琼脂稀释法分别对革兰氏阳性球菌和革兰氏阴性杆菌进行磺酸钠的 AST 测试。磺酸钠对革兰氏阳性病原体具有活性,最小抑菌浓度 90(MIC)值(g/L)分别为 MRSA 0.25、MSSA 1、CoNS 16、 0.03、 0.125、≤0.015、≤0.015、草绿色链球菌 0.03、0.25、0.5 和 0.03(无血补充)。革兰氏阴性菌的 MIC 值要高得多。添加血液的培养基被证明不适合该药物的活性测试。磺酸钠可能是经典抗生素局部应用的替代品。尽管它已经在临床上使用了几十年,但仍需要进行精心设计的随机试验,以有效地复兴这种古老的抗菌药物。